All In Biotech

Drug Trial Radar · NCT05757570

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)

Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jul 3, 2023

Primary completion

Aug 12, 2026

Study completion Aug 12, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.

Conditions

  • Idiopathic Thrombocytopenic Purpura
  • Immune Thrombocytopenia
  • Warm Autoimmune Hemolytic Anemia
  • Cold Agglutinin Disease

Interventions

  • PovetaciceptDrug

    Administered by subcutaneous injection every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability as Assessed by Adverse events (AEs) and Serious adverse events (SAEs)Time frame: Study Day 1 through 30 days after last dose of study drug

Locations

44 sites in 10 countries. Site status is shown where the registry gives one.

  • Investigational Site (230)

    Los Angeles, California

  • Investigational Site (401)

    Washington D.C., District of Columbia

  • Investigational Site (419)

    Cooper City, Florida

  • Investigational Site (425)

    Miami, Florida

  • Investigational Site (219)

    Iowa City, Iowa

  • Investigational Site (435)

    Columbia, Maryland

  • Investigational site (405)

    Lake Success, New York

  • Investigational Site (423)

    New Hyde Park, New York

  • Investigational Site (421)

    New York, New York

  • Investigational Site (404)

    New York, New York

  • Investigational Site (420)

    Shirley, New York

  • Investigational Site (422)

    The Bronx, New York

  • Investigational Site (414)

    Charlotte, North Carolina

  • Investigational Site (402)

    Greenville, North Carolina

  • Investigational Site (411)

    Seattle, Washington

  • Investigational Site (410)

    Box Hill, Australia

  • Investigational Site (519)

    Concord, Australia

  • Investigational Site (517)

    Douglas, Australia

  • Investigational Site (413)

    Liverpool, Australia

  • Investigational Site (407)

    West Perth, Australia

  • Investigational Site (409)

    Westmead, Australia

  • Investigational Site (434)

    Vienna, Austria

  • Investigational Site (406)

    Greenfield Park, Canada

  • Investigational Site (403)

    Hamilton, Canada

  • Investigational Site (444)

    Toronto, Canada

  • Investigational Site (438)

    Essen, Germany

  • Investigational Site (432)

    Meldola, Italy

  • Investigational Site (428)

    Milan, Italy

  • Investigational Site (431)

    Novara, Italy

  • Investigational Site (443)

    Trieste, Italy

  • Investigational Site (433)

    Grålum, Norway

  • Investigational Site (437)

    Trondheim, Norway

  • Investigational Site (436)

    Barcelona, Spain

  • Investigational Site (429)

    Burgos, Spain

  • Investigational Site (430)

    Madrid, Spain

  • Investigational Site (426)

    Murcia, Spain

  • Investigational Site (427)

    Seville, Spain

  • Investigational Site (415)

    Ankara, Turkey (Türkiye)

  • Investigational Site (416)

    Ankara, Turkey (Türkiye)

  • Investigational Site (418)

    Istanbul, Turkey (Türkiye)

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.